---
schema_version: "secwatch.filing_event.v1"
accession: "0001171520-22-000133"
form_type: "8-K"
ticker: "CLPT"
cik: "0001285550"
company_name: "ClearPoint Neuro, Inc."
filed_at: "2022-02-15T23:59:59+00:00"
generated_at: "2026-06-27T07:52:20.308559+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ClearPoint Neuro reports Q4 rev $4.3M (+15% YoY); FY2021 rev record $16.3M (+27% YoY); 2022 guidance $20-22M

## Summary
- Q4 2021 revenue $4.3M, up 15% YoY; functional neurosurgery products $2.1M (+37%), biologics/drug delivery $1.7M (+10%).
- Full-year 2021 record revenue $16.3M (+27% YoY) and record case volume 929 (+36% YoY), within initial guidance of $16-17.5M.
- Cash and equivalents $54.1M at year-end; management states no need for additional capital in 2022.
- 2022 revenue guidance $20-22M, representing growth of 23-35% YoY; COVID variant risk cited as key factor.
- Earnings call scheduled for March 1, 2022 after market close.

## SEC filing metadata
- accession: 0001171520-22-000133
- form_type: 8-K
- ticker: CLPT
- cik: 0001285550
- company_name: ClearPoint Neuro, Inc.
- filed_at: 2022-02-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1285550/000117152022000133/0001171520-22-000133-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1285550/000117152022000133/eps10071_clpt.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171520-22-000133
- JSON: https://secwatch.observer/filing/0001171520-22-000133.json
- Plain text: https://secwatch.observer/filing/0001171520-22-000133.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.